<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01451658</url>
  </required_header>
  <id_info>
    <org_study_id>V99C1-026;V100C-024</org_study_id>
    <nct_id>NCT01451658</nct_id>
  </id_info>
  <brief_title>Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With Hepatocellular Carcinoma</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei Veterans General Hospital, Taiwan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with hepatocellular carcinoma and esophageal varices bleeding were randomized to
      undergo endoscopic ligation alone (group A) and additive propranolol treatment (group B)
      after stabilization of their first acute bleeding.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Esophageal variceal bleeding is characteristic of high rebleeding rate and mortality. Thanks
      to the recent advance of treatment for variceal bleeding such as non-selective beta blocker
      (NSBB) added to endoscopic ligation further reduce rebleeding in cirrhotic patients, the
      rebleeding rate and mortality has a marked reduction. However, hepatocellular carcinoma (HCC)
      is a distinct group characteristic of very poor prognosis in patients with portal
      hypertension when compared to those of liver cirrhosis only. Therefore, the investigators
      design a study to randomize patients with HCC and acute variceal bleeding to endoscopic
      treatment alone and combination with endoscopic treatment and NSBB. This is the two years
      study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2009</start_date>
  <completion_date type="Anticipated">October 2012</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rebleeding</measure>
    <time_frame>2 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>complication survival</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Gastroesophageal Varices Hemorrhage</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>EVL or GVS treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Endoscopic treatment alone is used for 2nd prevention of gastroesophageal variceal bleeding in patients with HCC.
endoscopic variceal ligation (EVL) or Gastric Variceal Sclerotherapy (GVS)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endoscopic treatment alone versus combined propranolol</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Endoscopic treatment alone versus combined propranolol is used for 2nd prevention of gastroesophageal variceal bleeding in patients with HCC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propranolol</intervention_name>
    <description>Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period</description>
    <arm_group_label>Endoscopic treatment alone versus combined propranolol</arm_group_label>
    <other_name>propranolol:Inderal,Cardolol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. clinical diagnosis of HCC

          2. endoscopically proven acute variceal bleeding

          3. younger than 18 years old or older than 80 years old

        Exclusion Criteria:

        -Had a terminal illness of any major organ system,such as heart failure, kidney
        failure,COPD
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Veteran General Hospital-Taipei</name>
      <address>
        <city>Taipei</city>
        <state>Ming-Chih Hou, MD</state>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming Chih Hou, MD</last_name>
      <phone>886-2-28712121</phone>
      <phone_ext>3763</phone_ext>
      <email>mchou@vghtpe.gov.tw</email>
    </contact>
    <investigator>
      <last_name>Ming Chih Hou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2011</study_first_submitted>
  <study_first_submitted_qc>October 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2011</study_first_posted>
  <last_update_submitted>October 13, 2011</last_update_submitted>
  <last_update_submitted_qc>October 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Variceal bleeding</keyword>
  <keyword>portal hypertension</keyword>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>endoscopic variceal ligation</keyword>
  <keyword>non-selective beta-blocker</keyword>
  <keyword>rebleeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

